Skip to main content

Table 2 Clinical characteristics and ART use among adherence study participants with matched ECS data available, and their representativeness with respect to women enrolled in the ECS

From: Adherence to antiretroviral therapy during pregnancy and the first year postpartum among HIV-positive women in Ukraine

  Adherence study  
  Antenatal survey and ECS (n=97) Postnatal survey and ECS (n=44) ECS enrolment only (n = 1596)
Age at leaving full-time education    
≤16 years 1 (6%) 2 (9%) 204 (26%)
17 years or above 15 (94%) 20 (91%) 595 (74%)
History of injecting drug use    
No 87 (90%) 35 (80%) 1398 (88%)
Yes 10 (10%) 9 (20%) 191 (12%)
History of pregnancy termination    
0 40 (45%) 14 (39%) 540 (41%)
1 27 (31%) 8 (22%) 338 (26%)
2 or more 21 (24%) 14 (39%) 435 (33%)
Timing of HIV diagnosis    
Before pregnancy 44 (46%) 23 (52%) 693 (44%)
1st/2nd trimesters 48 (50%) 21 (48%) 736 (46%)
3rd trimester/intrapartum 4 (4%) 0 159 (10%)
Antenatal CD4 count (first in pregnancy)    
≤350 cells/mm3 19 (28%) 26 (76%) 484 (39%)
>350 cells/mm3 48 (72%) 8 (24%) 773 (61%)
WHO stage    
1-2 67 (78%) 25 (61%) 1160 (81%)
3-4 19 (22%) 16 (39%) 269 (19%)
Timing of ART initiation    
Before conception 7 (8%) 7 (17%) 95 (7%)
1st/2nd trimester 61 (66%) 23 (56%) 929 (65%)
3rd trimester 25 (27%) 11 (27%) 402 (28%)
Antenatal ART regimen    
Mono/dual 11 (12%) 3 (7%) 314 (22%)
cART 83 (88%) 39 (93%) 1139 (78%)
Median weeks on ART by completion of adherence survey 13.7 (IQR 11.3, 17) 43.7 (IQR 26.0, 54.9)